ObsEva Ends Linzagolix Launch Plans, Casting Another Shadow Over Women's Health
The Swiss drug maker will initiate a "mass dismissal" and return rights to its lead drug candidate after the US FDA alerted the company to NDA deficiencies.
You may also be interested in...
The Swiss firm has divested yet another one of its key programs in a bid to stave off insolvency and remain a listed company, forcing it to focus solely on a pre-IVF drug candidate.
Myovant and partner Pfizer have expected a slow ramp for Myfembree in uterine fibroids and new indication endometriosis as they build awareness and grow the market for the GnRH antagonist class.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker